ARTVArtiva Biotherapeutics Inc

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

Artiva announced a $300 million public offering to support the development of its autoimmune disease therapies, but at a 9% discount per share compared to Thursday’s closing price.

(RTTNews) - Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants...

Needham & Company LLC reissued a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Monday...

Wall Street Zen downgraded Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are covering the stock, Marketbeat.com reports. One...

Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Monday...

Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said...